TISIDB

Summary
Symbol	NOS3
Name	nitric oxide synthase 3 (endothelial cell)
Aliases	ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Note=Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity.
Domain	PF00667 FAD binding domain PF00258 Flavodoxin PF00175 Oxidoreductase NAD-binding domain PF02898 Nitric oxide synthase
Function	Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.; FUNCTION: Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0000303 response to superoxide GO:0000305 response to oxygen radical GO:0001525 angiogenesis GO:0001542 ovulation from ovarian follicle GO:0001667 ameboidal-type cell migration GO:0001701 in utero embryonic development GO:0001974 blood vessel remodeling GO:0001990 regulation of systemic arterial blood pressure by hormone GO:0002026 regulation of the force of heart contraction GO:0002028 regulation of sodium ion transport GO:0002237 response to molecule of bacterial origin GO:0003012 muscle system process GO:0003013 circulatory system process GO:0003015 heart process GO:0003018 vascular process in circulatory system GO:0003044 regulation of systemic arterial blood pressure mediated by a chemical signal GO:0003057 regulation of the force of heart contraction by chemical signal GO:0003073 regulation of systemic arterial blood pressure GO:0003100 regulation of systemic arterial blood pressure by endothelin GO:0006140 regulation of nucleotide metabolic process GO:0006164 purine nucleotide biosynthetic process GO:0006182 cGMP biosynthetic process GO:0006520 cellular amino acid metabolic process GO:0006525 arginine metabolic process GO:0006527 arginine catabolic process GO:0006801 superoxide metabolic process GO:0006809 nitric oxide biosynthetic process GO:0006813 potassium ion transport GO:0006814 sodium ion transport GO:0006816 calcium ion transport GO:0006979 response to oxidative stress GO:0007263 nitric oxide mediated signal transduction GO:0007292 female gamete generation GO:0007548 sex differentiation GO:0007596 blood coagulation GO:0007599 hemostasis GO:0008015 blood circulation GO:0008016 regulation of heart contraction GO:0008217 regulation of blood pressure GO:0008406 gonad development GO:0008585 female gonad development GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors GO:0009063 cellular amino acid catabolic process GO:0009064 glutamine family amino acid metabolic process GO:0009065 glutamine family amino acid catabolic process GO:0009150 purine ribonucleotide metabolic process GO:0009152 purine ribonucleotide biosynthetic process GO:0009165 nucleotide biosynthetic process GO:0009187 cyclic nucleotide metabolic process GO:0009190 cyclic nucleotide biosynthetic process GO:0009260 ribonucleotide biosynthetic process GO:0009266 response to temperature stimulus GO:0009408 response to heat GO:0009636 response to toxic substance GO:0010035 response to inorganic substance GO:0010543 regulation of platelet activation GO:0010544 negative regulation of platelet activation GO:0010631 epithelial cell migration GO:0010959 regulation of metal ion transport GO:0014738 regulation of muscle hyperplasia GO:0014740 negative regulation of muscle hyperplasia GO:0014745 negative regulation of muscle adaptation GO:0014805 smooth muscle adaptation GO:0014806 smooth muscle hyperplasia GO:0014900 muscle hyperplasia GO:0015672 monovalent inorganic cation transport GO:0016054 organic acid catabolic process GO:0019430 removal of superoxide radicals GO:0019932 second-messenger-mediated signaling GO:0022602 ovulation cycle process GO:0030168 platelet activation GO:0030193 regulation of blood coagulation GO:0030195 negative regulation of blood coagulation GO:0030323 respiratory tube development GO:0030324 lung development GO:0030728 ovulation GO:0030799 regulation of cyclic nucleotide metabolic process GO:0030801 positive regulation of cyclic nucleotide metabolic process GO:0030802 regulation of cyclic nucleotide biosynthetic process GO:0030804 positive regulation of cyclic nucleotide biosynthetic process GO:0030808 regulation of nucleotide biosynthetic process GO:0030810 positive regulation of nucleotide biosynthetic process GO:0030823 regulation of cGMP metabolic process GO:0030825 positive regulation of cGMP metabolic process GO:0030826 regulation of cGMP biosynthetic process GO:0030828 positive regulation of cGMP biosynthetic process GO:0031279 regulation of cyclase activity GO:0031281 positive regulation of cyclase activity GO:0031282 regulation of guanylate cyclase activity GO:0031284 positive regulation of guanylate cyclase activity GO:0031663 lipopolysaccharide-mediated signaling pathway GO:0032102 negative regulation of response to external stimulus GO:0032496 response to lipopolysaccharide GO:0032768 regulation of monooxygenase activity GO:0034405 response to fluid shear stress GO:0034599 cellular response to oxidative stress GO:0034614 cellular response to reactive oxygen species GO:0035150 regulation of tube size GO:0042311 vasodilation GO:0042312 regulation of vasodilation GO:0042698 ovulation cycle GO:0043266 regulation of potassium ion transport GO:0043267 negative regulation of potassium ion transport GO:0043271 negative regulation of ion transport GO:0043500 muscle adaptation GO:0043502 regulation of muscle adaptation GO:0043542 endothelial cell migration GO:0044057 regulation of system process GO:0044282 small molecule catabolic process GO:0045137 development of primary sexual characteristics GO:0045454 cell redox homeostasis GO:0045765 regulation of angiogenesis GO:0045766 positive regulation of angiogenesis GO:0045776 negative regulation of blood pressure GO:0045909 positive regulation of vasodilation GO:0045981 positive regulation of nucleotide metabolic process GO:0046068 cGMP metabolic process GO:0046209 nitric oxide metabolic process GO:0046390 ribose phosphate biosynthetic process GO:0046395 carboxylic acid catabolic process GO:0046545 development of primary female sexual characteristics GO:0046660 female sex differentiation GO:0048511 rhythmic process GO:0048514 blood vessel morphogenesis GO:0048608 reproductive structure development GO:0048771 tissue remodeling GO:0050817 coagulation GO:0050818 regulation of coagulation GO:0050819 negative regulation of coagulation GO:0050865 regulation of cell activation GO:0050866 negative regulation of cell activation GO:0050878 regulation of body fluid levels GO:0050880 regulation of blood vessel size GO:0050886 endocrine process GO:0050999 regulation of nitric-oxide synthase activity GO:0051051 negative regulation of transport GO:0051339 regulation of lyase activity GO:0051341 regulation of oxidoreductase activity GO:0051346 negative regulation of hydrolase activity GO:0051349 positive regulation of lyase activity GO:0051924 regulation of calcium ion transport GO:0051926 negative regulation of calcium ion transport GO:0052652 cyclic purine nucleotide metabolic process GO:0060047 heart contraction GO:0060541 respiratory system development GO:0061041 regulation of wound healing GO:0061045 negative regulation of wound healing GO:0061458 reproductive system development GO:0070838 divalent metal ion transport GO:0071216 cellular response to biotic stimulus GO:0071219 cellular response to molecule of bacterial origin GO:0071222 cellular response to lipopolysaccharide GO:0071396 cellular response to lipid GO:0071450 cellular response to oxygen radical GO:0071451 cellular response to superoxide GO:0072511 divalent inorganic cation transport GO:0072522 purine-containing compound biosynthetic process GO:0072593 reactive oxygen species metabolic process GO:0090066 regulation of anatomical structure size GO:0090130 tissue migration GO:0090132 epithelium migration GO:0090257 regulation of muscle system process GO:0097191 extrinsic apoptotic signaling pathway GO:0098754 detoxification GO:0098869 cellular oxidant detoxification GO:1900046 regulation of hemostasis GO:1900047 negative regulation of hemostasis GO:1900371 regulation of purine nucleotide biosynthetic process GO:1900373 positive regulation of purine nucleotide biosynthetic process GO:1900542 regulation of purine nucleotide metabolic process GO:1900544 positive regulation of purine nucleotide metabolic process GO:1901293 nucleoside phosphate biosynthetic process GO:1901342 regulation of vasculature development GO:1901565 organonitrogen compound catabolic process GO:1901605 alpha-amino acid metabolic process GO:1901606 alpha-amino acid catabolic process GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1903034 regulation of response to wounding GO:1903035 negative regulation of response to wounding GO:1903409 reactive oxygen species biosynthetic process GO:1903522 regulation of blood circulation GO:1903524 positive regulation of blood circulation GO:1904018 positive regulation of vasculature development GO:1990748 cellular detoxification GO:2001057 reactive nitrogen species metabolic process GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function	GO:0003779 actin binding GO:0003785 actin monomer binding GO:0004497 monooxygenase activity GO:0004517 nitric-oxide synthase activity GO:0005506 iron ion binding GO:0005516 calmodulin binding GO:0010181 FMN binding GO:0016597 amino acid binding GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016709 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen GO:0020037 heme binding GO:0031406 carboxylic acid binding GO:0034617 tetrahydrobiopterin binding GO:0034618 arginine binding GO:0043168 anion binding GO:0046870 cadmium ion binding GO:0046906 tetrapyrrole binding GO:0048037 cofactor binding GO:0050660 flavin adenine dinucleotide binding GO:0050661 NADP binding GO:0050662 coenzyme binding GO:0097110 scaffold protein binding
Cellular Component	GO:0005901 caveola GO:0030139 endocytic vesicle GO:0030659 cytoplasmic vesicle membrane GO:0030666 endocytic vesicle membrane GO:0044853 plasma membrane raft GO:0045121 membrane raft GO:0098589 membrane region GO:0098857 membrane microdomain

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04020 Calcium signaling pathway hsa04022 cGMP-PKG signaling pathway hsa04066 HIF-1 signaling pathway hsa04071 Sphingolipid signaling pathway hsa04151 PI3K-Akt signaling pathway hsa04370 VEGF signaling pathway hsa04611 Platelet activation hsa04915 Estrogen signaling pathway hsa04921 Oxytocin signaling pathway hsa00330 Arginine and proline metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-1430728: Metabolism R-HSA-202131: Metabolism of nitric oxide R-HSA-203754: NOSIP mediated eNOS trafficking R-HSA-203641: NOSTRIN mediated eNOS trafficking R-HSA-392154: Nitric oxide stimulates guanylate cyclase R-HSA-418346: Platelet homeostasis R-HSA-1222556: ROS, RNS production in phagocytes R-HSA-162582: Signal Transduction R-HSA-194138: Signaling by VEGF R-HSA-1474151: Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218920: VEGFR2 mediated vascular permeability R-HSA-203615: eNOS activation R-HSA-203765: eNOS activation and regulation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04020 Calcium signaling pathway
hsa04022 cGMP-PKG signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04071 Sphingolipid signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04370 VEGF signaling pathway
hsa04611 Platelet activation
hsa04915 Estrogen signaling pathway
hsa04921 Oxytocin signaling pathway
hsa00330 Arginine and proline metabolism
hsa01100 Metabolic pathways

Reactome

R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-202131: Metabolism of nitric oxide
R-HSA-203754: NOSIP mediated eNOS trafficking
R-HSA-203641: NOSTRIN mediated eNOS trafficking
R-HSA-392154: Nitric oxide stimulates guanylate cyclase
R-HSA-418346: Platelet homeostasis
R-HSA-1222556: ROS, RNS production in phagocytes
R-HSA-162582: Signal Transduction
R-HSA-194138: Signaling by VEGF
R-HSA-1474151: Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218920: VEGFR2 mediated vascular permeability
R-HSA-203615: eNOS activation
R-HSA-203765: eNOS activation and regulation

Summary
Symbol	NOS3
Name	nitric oxide synthase 3 (endothelial cell)
Aliases	ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NOS3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between NOS3 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24259296	Lung Carcinoma	Inhibit immunity	The production of PNT in G-MDSC depended on the expression of gp91(phox) and endothelial NO synthase (eNOS), while inducible NO synthase (iNOS) mediated the generation of NO in Mo-MDSC. Deletion of eNOS and gp91(phox) or scavenging of PNT blocked the suppressive function of G-MDSC and induced anti-tumoral effects, without altering Mo-MDSC inhibitory activity.

Summary
Symbol	NOS3
Name	nitric oxide synthase 3 (endothelial cell)
Aliases	ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NOS3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NOS3
Name	nitric oxide synthase 3 (endothelial cell)
Aliases	ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NOS3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.229	0.45
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.363	0.655
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.13	0.833
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.06	0.889
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.621	0.741
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.65	0.784
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.292	0.436
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.068	0.927
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.561	0.479
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.532	0.205
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.001	0.245
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.216	0.086

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NOS3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	1.4	6	0.177
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	12.5	-12.5	0.52
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	22.2	-22.2	0.505
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	3.7	1.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NOS3
Name	nitric oxide synthase 3 (endothelial cell)
Aliases	ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NOS3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NOS3
Name	nitric oxide synthase 3 (endothelial cell)
Aliases	ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NOS3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NOS3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NOS3
Name	nitric oxide synthase 3 (endothelial cell)
Aliases	ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NOS3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NOS3
Name	nitric oxide synthase 3 (endothelial cell)
Aliases	ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NOS3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NOS3
Name	nitric oxide synthase 3 (endothelial cell)
Aliases	ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NOS3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NOS3
Name	nitric oxide synthase 3 (endothelial cell)
Aliases	ECNOS; eNOS; endothelial nitric oxide synthase; EC-NOS; NOS type III; NOSIII; cNOS; endothelial NOS; nitric ......
Chromosomal Location	7q36
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NOS3 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting NOS3.

ID	Name	Drug Type	Targets	#Targets
DB00125	L-Arginine	Small Molecule	ARG2, ASL, ASS1, AZIN2, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4	9
DB00155	L-Citrulline	Small Molecule	ASS1, DDAH1, DDAH2, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PA ......	12
DB00360	Sapropterin	Small Molecule	NOS3, PAH, TH, TPH1	4
DB01110	Miconazole	Small Molecule	KCNH2, KCNH6, KCNH7, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1 ......	15
DB01686	N,N-dimethylarginine	Small Molecule	NOS2, NOS3	2
DB01821	L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide	Small Molecule	NOS1, NOS3	2
DB01833	L-2-Amino-4-(Guanidinooxy)Butyric Acid	Small Molecule	NOS3	1
DB01997	3-Bromo-7-Nitroindazole	Small Molecule	NOS1, NOS2, NOS3	3
DB02027	N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-Nitroguanidine	Small Molecule	NOS1, NOS3	2
DB02044	N-(3-(Aminomethyl)Benzyl)Acetamidine	Small Molecule	NOS1, NOS2, NOS3	3
DB02048	1,2,4-Triazole-Carboxamidine	Small Molecule	NOS3	1
DB02077	L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide	Small Molecule	NOS1, NOS3	2
DB02141	S,S'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea	Small Molecule	NOS3	1
DB02207	7-Nitroindazole	Small Molecule	NOS2, NOS3	2
DB02234	S-Ethylisothiourea	Small Molecule	NOS2, NOS3	2
DB02335	2-Aminothiazoline	Small Molecule	NOS3	1
DB02589	Se-Ethyl-Isoselenourea	Small Molecule	NOS3	1
DB02911	2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine	Small Molecule	NOS3	1
DB02979	N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane	Small Molecule	NOS3	1
DB02994	Cacodylic acid	Small Molecule	AKR1B1, GNAT1, NOS3	3
DB03065	7-Nitroindazole-2-Carboxamidine	Small Molecule	NOS3	1
DB03100	6-Nitroindazole	Small Molecule	NOS2, NOS3	2
DB03144	N-Omega-Hydroxy-L-Arginine	Small Molecule	ARG1, NOS1, NOS2, NOS3	4
DB03305	N5-Iminoethyl-L-Ornithine	Small Molecule	NOS3	1
DB03332	5,6-Cyclic-Tetrahydropteridine	Small Molecule	NOS3	1
DB03707	S-Ethyl-N-Phenyl-Isothiourea	Small Molecule	NOS1, NOS3	2
DB03910	S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea	Small Molecule	NOS3	1
DB03918	6S-5,6,7,8-Tetrahydrobiopterin	Small Molecule	NOS3	1
DB03963	S-(Dimethylarsenic)Cysteine	Small Molecule	COPG1, NOS3, TLR2, XRCC4	4
DB03974	L-Homoarginine	Small Molecule	NOS3	1
DB04018	S-Isopropyl-Isothiourea	Small Molecule	NOS3	1
DB04223	Nitroarginine	Small Molecule	NOS1, NOS3	2
DB04534	5-Nitroindazole	Small Molecule	NOS2, NOS3	2
DB04559	N-(Chlorophenyl)-N'-Hydroxyguanidine	Small Molecule	NOS3	1
DB05676	Apremilast	Small Molecule	IFNG, IL2, NOS3, PDE4A, PDE4B, PDE4D, TNF	7
DB07001	(3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine	Small Molecule	NOS3	1
DB07244	5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE	Small Molecule	NOS3, REN	2
DB07388	ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE	Small Molecule	NOS2, NOS3	2
DB08018	N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE	Small Molecule	NOS1, NOS3	2
DB08019	N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine	Small Molecule	NOS1, NOS3	2
DB09237	Levamlodipine	Small Molecule	CACNA1C, NOS2, NOS3	3

Browse NOS3